ADVANCES IN VACCINE DEVELOPMENT: MRNA TECHNOLOGY BEYOND COVID-19

Authors

  • Dr. Hina Riaz, Department of Microbiology, University of the Punjab, Lahore, Pakistan Author
  • Dr. Faisal Ahmed Department of Biological & Biomedical Sciences, Aga Khan University, Karachi, Pakistan Author
  • Dr. Laura J. Collins Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK Author
  • Dr. Kenji Tanaka, Department of Vaccine Science, Graduate School of Medicine, The University of Tokyo, Japan Author

DOI:

https://doi.org/10.71465/jhmri68

Keywords:

mRNA vaccines, RSV, influenza, CMV, cancer vaccines, lipid nanoparticles, self-amplifying RNA

Abstract

Messenger RNA (mRNA) platforms matured rapidly during the COVID-19 pandemic, establishing a new, programmable class of vaccines. Beyond SARS-CoV-2, the field has advanced along three fronts: (i) expanded indications—with regulatory approval for adult RSV (mRNA-1345/mRESVIA) and late-stage programs in seasonal influenza and cytomegalovirus (CMV); (ii) therapeutic vaccination, notably personalized neoantigen vaccines that augment immune checkpoint blockade; and (iii) platform innovation, including self-amplifying RNA (saRNA), circular RNA (circRNA), and improved lipid nanoparticle (LNP) delivery and thermostabilization. We review these advances, the clinical landscape, manufacturing and regulatory considerations, and outstanding challenges in durability, breadth, and equitable access. The trajectory suggests mRNA vaccines will anchor future routine immunization and oncology care, contingent on delivery and cost innovations.

image

Downloads

Published

2023-12-31

Issue

Vol. 1 No. 4 (2023): Journal of Health, Medical Research and Innovations

Section

Articles

License

Copyright (c) 2023 Dr. Hina Riaz, , Dr. Faisal Ahmed, Dr. Laura J. Collins, Dr. Kenji Tanaka, (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

All articles published in the Journal of Health, Medical Research and Innovations are distributed under an open access license. Authors retain copyright and grant the journal the right of first publication. The published content can be freely accessed, shared, and reused for non-commercial purposes, provided proper citation is maintained and the original work is not altered.